Clinical studies recruiting near Tianjin

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · Institute of hematology&blood disease hospital · Pfizer · NCT05020236 Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
Phase 3 · First Teaching Hospital of Tianjin University of Traditional · Tasly Pharmaceutical Group Co., Ltd · NCT07687186 A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · The Second Hospital of Tianjin Medical University · Eli Lilly and Company · NCT07218380 A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart
Phase 3 · CON-56003, Tianjin, Tianjin · Colorado Prevention Center · NCT06024746 This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
Phase 1 · Institute of Hematology and Blood Diseases Hospital, Chinese · Nanjing RegeneCore Biotech Co., Ltd. · NCT06756451 Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3 · Tianjin Medical University Cancer Institute & Hospital · Daiichi Sankyo · NCT07022483 DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Phase 2 · Institute of Hematology & Blood Diseases Hospital Chinese Ac · Institute of Hematology & Blood Diseases Hospital, China · NCT06158269 The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Phase 1/Phase 2 · Institute of Hematology & Blood Diseases Hospital, Chinese A · Lin BioScience, Inc · NCT05756322 Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
Phase 2 · Department of Radiation Oncology, Tianjin Medical University · Tianjin Medical University Cancer Institute and Hospital · NCT07726446 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · Tianjin Medical University Cancer Institute & Hospital-lymph · Merck Sharp & Dohme LLC · NCT06136559 Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease
Phase 2/Phase 3 · Tianjin Medical University Cancer Institute & Hospital · Bristol-Myers Squibb · NCT07106762 Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
Phase N/A · Tianjin Medical University General Hospital · Tianjin Medical University · NCT07685873 Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 · InstituteHBDH · CytoCares Inc · NCT06037018 This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Tianjin Medical University General Hospital · Pfizer · NCT06758401 A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Phase 3 · Local Institution - 0183 · Bristol-Myers Squibb · NCT06929273 Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Mod
Phase 3 · Chinese Academy of Medical Sciences Hematology Hospital · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06682169 IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes
NA · Tianjin Medical University General Hospital · Jinling Hospital, China · NCT06118840 Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Phase 2 · Tianjin Cancer Hospital Airport Hospital · Tianjin Medical University Cancer Institute and Hospital · NCT07528274 Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-smal
Phase 2/Phase 3 · First Teaching Hospital of Tianjin University of Traditional · Kong Fanming · NCT07034326 Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
EARLY_Phase 1 · Tianjin Medical University General Hospital · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05145361 A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
Phase 2 · Hematology Hospital of the Chinese Academy of Medical Scienc · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06300320 A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/Phase 2 · Tianjin Cancer Hospital · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06431490 IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1/Phase 2 · Tianjin Medical University Cancer Institute & Hospital · InxMed (Shanghai) Co., Ltd. · NCT06030258 Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
Phase N/A · Tianjin Medical University General Hospital · Tianjin Medical University · NCT07618936 The Chinese Familial Alzheimer's Network
Phase N/A · Capital Medical University · NCT03657732 Randomization of Single vs Multiple Arterial Grafts
NA · Teda Hospital (TICH) · Weill Medical College of Cornell University · NCT03217006 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-I
Phase 2 · Institute of Hematology and Blood Diseases Hospital Chinese · Institute of Hematology & Blood Diseases Hospital, China · NCT05979363 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Tianjin Peoples Hospital · Amgen · NCT07037433 A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Phase 3 · Tianjin People's Hospital · Hasten Biopharmaceutical Co., Ltd. · NCT06568471 Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
Phase 2 · Tianjin Medical University Cancer Institute and Hospital · Tianjin Medical University Cancer Institute and Hospital · NCT07733830

Look up another city

Look up another condition